Cite
HARVARD Citation
Livingstone, E. et al. (2022). Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet. 400 (10358), pp. 1117-1129. [Online].